The cholesterol paradox revisited: heart failure, systemic inflammation, and beyond

Heart Failure Clinics
Stephan von HaehlingStefan D Anker

Abstract

The pathophysiologic understanding of chronic heart failure has made significant advances over the last decades. Counterintuitively, high levels of plasma cholesterol are associated with better survival, perhaps because plasma lipoproteins are able to scavenge lipopolysaccharide, a cell-wall component from gram-negative bacteria. A number of similar features are present in patients who have sepsis. This article explores the cholesterol paradox in patients who have chronic heart failure and extends this view to patients who have sepsis. Also discussed is the potential of statins, which might be able to exert beneficial effects in both clinical conditions, despite lowering plasma cholesterol values.

References

Feb 1, 1992·Infection and Immunity·K EmancipatorR J Elin
Jul 26, 1990·The New England Journal of Medicine·B LevineM Packer
Sep 1, 1990·The Journal of Clinical Investigation·H W HarrisJ H Rapp
Sep 1, 1988·Metabolism: Clinical and Experimental·K SammalkorpiM R Taskinen
Dec 1, 1994·The Clinical Investigator·E WindlerH Greten
May 1, 1995·Infection and Immunity·K R FeingoldC Grunfeld
Jul 1, 1995·The Journal of Experimental Medicine·T E ReadJ H Rapp
Dec 1, 1994·British Heart Journal·A MatsumoriS Sasayama
Dec 15, 1993·Proceedings of the National Academy of Sciences of the United States of America·D M LevineA L Rubin
Oct 1, 1996·Intensive Care Medicine·H D VolkW J Kox
Feb 1, 1997·European Heart Journal·M R CowieD E Grobbee
Jul 10, 1998·BMJ : British Medical Journal·W J MeerdingP J van der Maas
Dec 5, 1998·The New England Journal of Medicine·UNKNOWN Long-Term Intervention with Pravastatin in Ischaemic Disease (LIPID) Study Group
Jun 8, 1999·The Journal of Experimental Medicine·R ShimazuM Kimoto
Jan 15, 2000·Journal of the American College of Cardiology·C J VaughanC T Basson
Apr 18, 2000·Heart·J J McMurray, S Stewart
Oct 19, 2000·Lancet·M RauchhausS D Anker
Feb 24, 2001·The Journal of Immunology : Official Journal of the American Association of Immunologists·A VerbonT van der Poll
Mar 15, 2001·Cancer Letters·S Aznar, J C Lacal
Mar 29, 2001·Nature Immunology·K TriantafilouR L Dedrick
Apr 13, 2001·JAMA : the Journal of the American Medical Association·G G SchwartzUNKNOWN Myocardial Ischemia Reduction with Aggressive Cholesterol Lowering (MIRACL) Study Investigators
May 30, 2001·European Journal of Heart Failure·S StewartJ J McMurray
Aug 9, 2001·European Heart Journal·W J RemmeUNKNOWN Task Force for the Diagnosis and Treatment of Chronic Heart Failure, European Society of Cardiology
Jun 20, 2002·Trends in Immunology·Martha Triantafilou, Kathy Triantafilou
Aug 7, 2002·International Journal of Cardiology·Stefan D Anker, Rakesh Sharma
Aug 7, 2002·International Journal of Cardiology·S von HaehlingH D Volk
Oct 25, 2002·Journal of Cardiac Failure·Tamara B HorwichGregg C Fonarow
Nov 7, 2002·International Journal of Cardiology·Stefan D Anker, Andrew J S Coats
Nov 30, 2002·Expert Opinion on Investigational Drugs·Sanjay ManochaAnand Kumar
Mar 26, 2003·Heart Failure Reviews·Stephan von HaehlingEberhard Bassenge
May 29, 2003·Critical Care Medicine·Henk J van LeeuwenKok P M van Kessel
Dec 10, 2003·Journal of the American College of Cardiology·Mathias RauchhausStefan D Anker
Dec 20, 2003·Basic Research in Cardiology·Stephan von HaehlingStefan D Anker
Feb 21, 2004·Journal of the American College of Cardiology·Tamara B HorwichGregg C Fonarow
Mar 17, 2004·Heart·Stefan D Anker, Stephan von Haehling

❮ Previous
Next ❯

Citations

Jul 2, 2010·American Journal of Therapeutics·Ehab S El Desoky
Feb 25, 2015·International Journal of Cardiology·G GüderUNKNOWN Competence Network Heart Failure Germany
Jan 29, 2016·European Journal of Heart Failure·John ParissisGerasimos Filippatos
Oct 11, 2011·International Journal of Cardiology·Goran LoncarVera Popovic
Jul 6, 2015·Heart Failure Clinics·Naveen BellamDavid J Whellan
Mar 18, 2010·Nature Reviews. Cardiology·W H Wilson Tang, Gary S Francis
Dec 17, 2010·World Journal of Hepatology·Yuriy K BashmakovIvan M Petyaev
Oct 23, 2019·Minerva medica·Filipe M CunhaPatrícia Lourenço
Apr 24, 2010·Journal of Cardiovascular Medicine·Elena AbateGiovanni M Boffa
May 29, 2009·Current Opinion in Clinical Nutrition and Metabolic Care·Anja SandekStephan von Haehling
Nov 1, 2008·Clinical Science·Stephan von Haehling

❮ Previous
Next ❯

Related Concepts

Related Feeds

Cardiomyopathy

Cardiomyopathy is a disease of the heart muscle, that can lead to muscular or electrical dysfunction of the heart. It is often an irreversible disease that is associated with a poor prognosis. There are different causes and classifications of cardiomyopathies. Here are the latest discoveries pertaining to this disease.

Cardiac Cachexia

Cardiac cachexia is a syndrome associated with the progressive loss of muscle and fat mass. It most commonly affects patients with heart failure and can significantly decrease the quality of life and survival in these patients. Here is the latest research on cardiac cachexia.

Anti-inflammatory Treatments

A drug or substance that reduces inflammation (redness, swelling, and pain) in the body. Anti-inflammatory agents block certain substances in the body that cause inflammation and swelling. Discover the latest research on anti-inflammatory treatments here

ApoE, Lipids & Cholesterol

Serum cholesterol, triglycerides, apolipoprotein B (APOB)-containing lipoproteins (very low-density lipoprotein (VLDL), immediate-density lipoprotein (IDL), and low-density lipoprotein (LDL), lipoprotein A (LPA)) and the total cholesterol/high-density lipoprotein (HDL) cholesterol ratio are all connected in diseases. Here is the latest research.

Brain Ischemia

Brain ischemia is a condition in which there is insufficient blood flow to the brain to meet metabolic demand. Discover the latest research on brain ischemia here.